Get started
GILEAD SCIENCES DL-,001GILEAD SCIENCES DL-,001GILEAD SCIENCES DL-,001

GILEAD SCIENCES DL-,001

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Bonds

GIS trade ideas

Is GILD building out a bear channel for future shorting purposesOne look at GILD (and CELG and IIB) are showing pretty much the same pattern that MAY be building. And yes its a bear channel that we'd like to see build out for shorting purposes. That and an upward move to some resistance zones shown, but the market is the boss and its going to do what it wants to do. The market is the boss not us. If the pattern builds out it builds out. As with all I do its real simple, no pattern no trade. These are not recommendations, strictly for informational and educational purposes only.
NASDAQ:GILD
by Amazingpowerpatternguy
GILD H&S Forming?Just a hunch, but here's my .02 on GILD, one of the highest-flying Biotechs. Could be setting up for a massive H&S. Shows where left shoulder already formed, working on the head and my guesstimate ref. the right shoulder. At a minimum, is a great short candidate and a great low risk/high reward scenario b/c you can short it now and set stop at top of forming head ...110.64 +.01=110.65 for stop. TGT would be around 22ish, so that's a pretty good drop if it came to pass. TBD and will be fun to watch!
NASDAQ:GILDShort
by jmboyer1
2
Technicals Saying Take Profits On Gilead Sciences, Inc. (NASDAQ:The biotech sector has had an amazing run in 2014, and you could say that Gilead Sciences, Inc. (NASDAQ:GILD) has lead the charge. The biopharma company is up roughly 40% year to date, and this is after an amazing 100% return for investors in 2013. One could say this is a can't miss stock and rewards its shareholders extremely well. I am not trying to take anything away from the run that Gilead Sciences, Inc. (NASDAQ:GILD) has had. However, looking at the weekly chart I am seeing a bearish pattern being formed, and this indicates to me that there will be downside in the near future. The candlestick that has developed on the chart below is called, a "bearish engulfing candle" and it points to further weakness ahead. So how far can Gilead fall? The first meaningful level that I see is $84, as that is not only the break out area which lead to the recent run up to the all time high of $110.64. But there are also some key proprietary factors which should provide longs a 10% bounce at that level. So while this level may seem like it's far away, know this, the biotech sector can be extremely volatile and this level could be achieved easily in weeks, if not days. Keep a close eye on this chart as the trading action it presents will be fun and profitable! If you only read one email again, make sure it comes from the Elite Round Table. Our FREE market emails contain information that can actually make you money. Ask yourself, what email have you read that can do that? Answer = none. Join our list here. Parm Mann Elite Round Table Follow me on twitter: @ParmMannTrader
NASDAQ:GILD
by Parm
5
$GILD Cleared Psychological Pivot Point (Will it last)"Seeing is believing" it does not need a lot of explanation. Its true that price finally closed above PPP level, and seems to print the projected price of C/handle. If market eventually corrects as expected, this is one of the stocks many bears will try to hit hard as it outperformed the market in general. We don't recommend a long term short entry but expect a pull back towards 90-95 which will present another opportunity to re-enter this stock. Stay safe and tuned for more to come. If you like it follow us.
NASDAQ:GILD
by Xafada
1
GILD US, Sovaldi against Hepatitis C, LT BUY extreme potentialin at 82 catching early move, still must have Since December 2013 Sovaldi is available in the US and since January 2014 in some European countries while approvals in various significant markets are still pending. Based on its medical importance, I expect more launches in due time. Medicare (US national social insurance program) projects costs of USD 6.5bn in 2015 related to Sovaldi (US only). Until recently, Hepatitis C patients have been treated with a combination of injections and the effect was only to stabilize the disease but not to heal it. In addition, side effects were significant. Sovaldi can be applied in the much easier form of pills. Furthermore, Sovaldi can completely cure Hepatitis C within weeks, as results have shown. The Swiss Department of Health assumes that 1% of total population is infected with the Hepatitis C virus, thus approximately 80’000 people in Switzerland. Extrapolated, Europe would have 7.5m potential patients and worldwide there will be 80m potential patients. Costs of treatment are currently USD 84’000 per patient (in the US). Enormous growth potential here.
NASDAQ:GILDLong
by TBO_ZH
GILD Another Bounce Play In the MakingDisclosure: Long Shares @ 68.09 On Friday, Mar 28th, I bought shares of GILD right at the 200-ma for a bounce play, this is one of the strongest biotech stocks and should continue to hold in an uptrend for at least a little while as its hit drug is tracking huge numbers in the market and the pipeline is strong, I think a buy here for a couple dollars bounce could definitely be playable as the RSI is oversold, and the 200 MA is being defended strongly
NASDAQ:GILDLong
by shomikghosh2
2